At the news
? NEUTRALIMPACT 4/10 8-K filed Feb 24, 2026 at 17:21 ET
Vaxcyte entered into an at-the-market (ATM) sales agreement with Leerink Partners LLC to sell up to $500 million in common stock. The company also terminated its prior ATM agreement with Jefferies LLC, under which it had raised approximately $270.3 million. This new facility provides Vaxcyte with ongoing access to capital markets, subject to market conditions and its discretion on timing and size of offerings.
- Vaxcyte entered into a new sales agreement with Leerink Partners LLC for an at-the-market equity offering program.
- The maximum aggregate offering amount under the new agreement is $500,000,000.
- The shares are registered under an existing shelf registration statement (Form S-3) that became effective on May 24, 2024.
- Leerink Partners will act as sales agent and receive a commission of up to 3.00% of the gross proceeds.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access